Table 5

Hypoglycaemic drug treatment among patients with diabetes who had and did not have a stroke from 2016 to 2018

Medication for diabetes	Non-stroke			Stroke
Medication for diabetes	2016	2017	2018	2016	2017	2018
Antidiabetic drugs	597 971	655 166	708 234	176 527	185 691	178 357
Monotherapy	246 553	254 992	265 046	65 327	63 812	58 605
AGIs	83 550	83 918	84 625	27 636	27 545	24 639
Metformin	77 889	89 781	101 412	16 277	18 112	18 496
Sulfonylureas	24 233	23 215	21 652	6186	5699	4793
Premixed insulin	35 507	31 869	28 366	10 096	7629	5772
DPP-4i	–	2218	5967	–	281	895
Glinides	8121	7185	6339	1861	1544	1287
Oral combination therapy	272 184	317 825	360 571	84 625	96 083	97 554
AGIs+metformin	53 616	64 650	74 068	16 279	19 732	20 409
AGIs+sulfonylurea	39 488	38 320	35 851	12 958	12 098	10 363
Metformin+sulfonylurea	37 573	41 128	42 197	8878	9272	8837
AGI+metformin+sulfonylurea	33 983	39 247	41 543	11 530	12 779	12 664
Metformin+DPP-4i	–	4094	11 267	–	471	1490
Metformin+glinides	10 049	9816	9161	2203	2112	1916
AGI+glinides	8028	7484	6815	2413	2271	1798
Oral+insulin	119 730	135 533	145 174	44 682	48 662	45 120
AGI+premixed insulin	23 464	23 407	21 830	10 583	10 070	8070
AGI+metformin+insulin	12 450	15 638	16 741	5574	7273	6655
Metformin+premixed insulin	13 740	15 018	14 942	4667	4537	3911

Values in the table represent the number of people who used the drug that year.
AGI, α-glucosidase inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor.